INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset
Summarize this article with:
AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA Stocks INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset December 18, 2025 — 07:59 am EST Written by Zacks Equity Research for Zacks-> Shares of Insmed INSM lost nearly 20% in after-market trading on Wednesday after the company announced the failure of a mid-stage study evaluating Brinsupri (brensocatib) in chronic rhinosinusitis without nasal polyps (CRSsNP).This phase IIb study, called BiRCh, failed to achieve either its primary or secondary efficacy endpoints. Although the drug was well-tolerated in patients, the results did not show any treatment benefit in patients compared with placebo, even at the highest dose level. Based on this outcome, Insmed decided to end development of Brinsupri in CRSsNP. This announcement surprised investors, who had been expecting positive results from the BiRCh study. Insmed had achieved a significant milestone with Brinsupri in August, when the FDA approved it as the first treatment for non-cystic fibrosis (non-CF) bronchiectasis. Post this approval, it became the second marketed product in Insmed’s portfolio after Arikayce (approved to treat a rare lung disease infection).Early commercial traction for Brinsupri has been encouraging — the drug generated $28 million in third-quarter 2025 sales despite receiving approval only in the middle of the quarter, reflecting strong initial uptake. Investors had expected this momentum to be further propelled by potential approval in new indications, such as CRSsNP, which have significant commercial potential.The BiRCh study results have also made investors less enthused about the phase II CEDAR study, which is evaluating Brinsupri in the hidradenitis suppurativa (HS) indication. An update on this study is expected in the first half of 2026.INSM Stock PerformanceThis marks the first major setback for Insmed in some time, as the company had delivered a series of positive updates leading up to this announcement. Following the sharp after-hours decline, the stock continued to trend lower in pre-market trading today.Year to date, shares of Insmed are still up 187% compared with the industry’s 18% growth. Image Source: Zacks Investment ResearchInsmed Expands Pipeline With New AcquisitionAlongside the BiRCh study results, Insmed announced that it has acquired an investigational monoclonal antibody, INS1148 (formerly OpSCF), from the privately-held biotech Opsidio. This drug is designed to address respiratory and immunological and inflammatory diseases by targeting a specific isoform of Stem Cell Factor SCF248.Insmed plans to initially develop INS1148 in mid-stage studies for interstitial lung disease and moderate-to-severe asthma.INSM’s Zacks RankInsmed currently carries a Zacks Rank #3 (Hold).Insmed, Inc. Price Insmed, Inc. price | Insmed, Inc. QuoteKey Picks Among Biotech StocksSome better-ranked stocks from the sector are ANI Pharmaceuticals ANIP and CorMedix CRMD, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here. In the past 60 days, estimates for ANI Pharmaceuticals’ 2025 earnings per share (EPS) have risen from $7.29 to $7.56. EPS estimates for 2026 have increased from $7.81 to $8.08 during the same period. Year to date, shares of ANIP have surged 49%.ANIP’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 21.24%.Estimates for CorMedix’s 2025 EPS have increased from $1.85 to $2.87 over the past 60 days, while the same for 2026 has increased from $2.49 to $2.88. CRMD shares have risen 41% year to date.CorMedix’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 27.04%.
Zacks Naming Top 10 Stocks for 2026 Want to be tipped off early to our 10 top picks for the entirety of 2026? History suggests their performance could be sensational. From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2026. Don’t miss your chance to get in on these stocks when they’re released on January 5. Be First to New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportInsmed, Inc. (INSM) : Free Stock Analysis ReportANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis ReportCorMedix Inc (CRMD) : Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Tags StocksInvesting Zacks Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com. More articles by this source-> Stocks mentioned INSM ANIP CRMD More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.